Altered levels of phospholipases C, diacylglycerols, endocannabinoids, and N-acylethanolamines in patients with hereditary angioedema due to FXII mutation.
2‐arachidonoylglycerol
anandamide
diacylglycerols
oleoylethanolamide
palmitoylethanolamide
Journal
Allergy
ISSN: 1398-9995
Titre abrégé: Allergy
Pays: Denmark
ID NLM: 7804028
Informations de publication
Date de publication:
27 Jun 2024
27 Jun 2024
Historique:
revised:
31
05
2024
received:
30
01
2024
accepted:
31
05
2024
medline:
27
6
2024
pubmed:
27
6
2024
entrez:
27
6
2024
Statut:
aheadofprint
Résumé
Hereditary angioedema (HAE) is a rare genetic disorder characterized by local, self-limiting edema due to temporary increase in vascular permeability. HAE with normal C1 esterase inhibitor (C1INH) activity includes the form with mutations in the F12 gene encoding for coagulation factor XII (FXII-HAE) causing an overproduction of bradykinin (BK) leading to angioedema attack. BK binding to B2 receptors (BK2R) leads to an activation of phospholipase C (PLC) and subsequent generation of second messengers: diacylglycerols (DAGs) and possibly the endocannabinoids (eCBs), 2-arachidonoylglycerol (2-AG) and anandamide (AEA), and eCB-related N-acylethanolamines [palmitoylethanolamide (PEA) and oleoylethanolamide (OEA)]. To date, there are no data on the role of these lipid mediators in FXII-HAE. Here, we analyzed plasma levels of PLC, DAGs, and eCBs in 40 patients with FXII-HAE and 40 sex- and age-matched healthy individuals. Plasma PLC activity was increased in FXII-HAE patients compared to controls. Concentrations of DAG 18:1-20:4, a lipid second messenger produced by PLC, were higher in FXII-HAE compared to controls, and positively correlated with PLC activity and cleaved high molecular kininogen (cHK). Also the concentrations of the DAG metabolite, 2-AG were altered in FXII-HAE. AEA and OEA were decreased in FXII-HAE patients compared to controls; by contrast, PEA, was increased. The levels of all tested mediators did not differ between symptomatic and asymptomatic patients. Moreover, C1INH-HAE patients had elevated plasma levels of PLC, which correlated with cHK, but the levels of DAGs and eCBs were the same as controls. BK overproduction and BKR2 activation are linked to alteration of PLCs and their metabolites in patients with FXII-HAE. Our results may pave way to investigations on the functions of these mediators in the pathophysiology of FXII-HAE, and provide new potential biomarkers and therapeutic targets.
Sections du résumé
BACKGROUND
BACKGROUND
Hereditary angioedema (HAE) is a rare genetic disorder characterized by local, self-limiting edema due to temporary increase in vascular permeability. HAE with normal C1 esterase inhibitor (C1INH) activity includes the form with mutations in the F12 gene encoding for coagulation factor XII (FXII-HAE) causing an overproduction of bradykinin (BK) leading to angioedema attack. BK binding to B2 receptors (BK2R) leads to an activation of phospholipase C (PLC) and subsequent generation of second messengers: diacylglycerols (DAGs) and possibly the endocannabinoids (eCBs), 2-arachidonoylglycerol (2-AG) and anandamide (AEA), and eCB-related N-acylethanolamines [palmitoylethanolamide (PEA) and oleoylethanolamide (OEA)]. To date, there are no data on the role of these lipid mediators in FXII-HAE.
METHODS
METHODS
Here, we analyzed plasma levels of PLC, DAGs, and eCBs in 40 patients with FXII-HAE and 40 sex- and age-matched healthy individuals.
RESULTS
RESULTS
Plasma PLC activity was increased in FXII-HAE patients compared to controls. Concentrations of DAG 18:1-20:4, a lipid second messenger produced by PLC, were higher in FXII-HAE compared to controls, and positively correlated with PLC activity and cleaved high molecular kininogen (cHK). Also the concentrations of the DAG metabolite, 2-AG were altered in FXII-HAE. AEA and OEA were decreased in FXII-HAE patients compared to controls; by contrast, PEA, was increased. The levels of all tested mediators did not differ between symptomatic and asymptomatic patients. Moreover, C1INH-HAE patients had elevated plasma levels of PLC, which correlated with cHK, but the levels of DAGs and eCBs were the same as controls.
CONCLUSIONS
CONCLUSIONS
BK overproduction and BKR2 activation are linked to alteration of PLCs and their metabolites in patients with FXII-HAE. Our results may pave way to investigations on the functions of these mediators in the pathophysiology of FXII-HAE, and provide new potential biomarkers and therapeutic targets.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : IIR-ITA-002138
Informations de copyright
© 2024 European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
Références
Bova M, Suffritti C, Bafunno V, et al. Impaired control of the contact system in hereditary angioedema with normal C1‐inhibitor. Allergy. 2020;75(6):1394‐1403.
Kaplan AP, Joseph K. The bradykinin‐forming cascade and its role in hereditary angioedema. Ann Allergy Asthma Immunol. 2010;104(3):193‐204.
Maurer M, Magerl M, Betschel S, et al. The international WAO/EAACI guideline for the management of hereditary angioedema‐the 2021 revision and update. Allergy. 2022;77(7):1961‐1990.
Dewald G, Bork K. Missense mutations in the coagulation factor XII (Hageman factor) gene in hereditary angioedema with normal C1 inhibitor. Biochem Biophys Res Commun. 2006;343(4):1286‐1289.
Bork K, Machnig T, Wulff K, Witzke G, Prusty S, Hardt J. Clinical features of genetically characterized types of hereditary angioedema with normal C1 inhibitor: a systematic review of qualitative evidence. Orphanet J Rare Dis. 2020;15(1):289.
Bork K, Wulff K, Witzke G, Hardt J. Hereditary angioedema with normal C1‐INH with versus without specific F12 gene mutations. Allergy. 2015;70(8):1004‐1012.
Farsetti A, Misiti S, Citarella F, et al. Molecular basis of estrogen regulation of Hageman factor XII gene expression. Endocrinology. 1995;136(11):5076‐5083.
de Maat S, Joseph K, Maas C, Kaplan AP. Blood clotting and the pathogenesis of types I and II hereditary angioedema. Clin Rev Allergy Immunol. 2021;60(3):348‐356.
Bossi F, Tedesco F. Role of the B1 bradykinin receptor and gC1qR/p33 in angioedema. Immunol Allergy Clin N Am. 2013;33(4):535‐544.
Blaukat A. Structure and signalling pathways of kinin receptors. Andrologia. 2003;35(1):17‐23.
Eichmann TO, Lass A. DAG tales: the multiple faces of diacylglycerol—stereochemistry, metabolism, and signaling. Cell Mol Life Sci. 2015;72(20):3931‐3952.
Reisenberg M, Singh PK, Williams G, Doherty P. The diacylglycerol lipases: structure, regulation and roles in and beyond endocannabinoid signalling. Philos Trans R Soc Lond Ser B Biol Sci. 2012;367(1607):3264‐3275.
Luchicchi A, Pistis M. Anandamide and 2‐arachidonoylglycerol: pharmacological properties, functional features, and emerging specificities of the two major endocannabinoids. Mol Neurobiol. 2012;46(2):374‐392.
Stanley CP, Hind WH, Tufarelli C, O’Sullivan SE. The endocannabinoid anandamide causes endothelium‐dependent vasorelaxation in human mesenteric arteries. Pharmacol Res. 2016;113:356‐363. doi:10.1016/j.phrs.2016.08.028
Baranowska‐Kuczko M, MacLean MR, Kozłowska H, Malinowska B. Endothelium‐dependent mechanisms of the vasodilatory effect of the endocannabinoid, anandamide, in the rat pulmonary artery. Pharmacol Res. 2012;66(3):251‐259. doi:10.1016/j.phrs.2012.05.004
Maccarrone M, Bari M, Lorenzon T, Bisogno T, Di Marzo V, Finazzi‐Agrò A. Anandamide uptake by human endothelial cells and its regulation by nitric oxide. J Biol Chem. 2000;275(18):13484‐13492. doi:10.1074/jbc.275.18.13484
AlSuleimani YM, Hiley CR. Mechanisms of vasorelaxation induced by oleoylethanolamide in the rat small mesenteric artery. Eur J Pharmacol. 2013;702(1–3):1‐11. doi:10.1016/j.ejphar.2013.01.006
Hind WH, Tufarelli C, Neophytou M, Anderson SI, England TJ, O’Sullivan SE. Endocannabinoids modulate human blood–brain barrier permeability in vitro. Br J Pharmacol. 2015;172(12):3015‐3027. doi:10.1111/bph.13106
Jehle J, Eich L, Danisch M, et al. The endocannabinoid 2‐arachidonoylglycerol inhibits endothelial function and repair. Int J Cardiol. 2021;323:243‐250. doi:10.1016/j.ijcard.2020.08.042
Scott CF, Shull B, Muller‐Esterl W, Colman RW. Rapid direct determination of low and high molecular weight kininogen in human plasma by particle concentration fluorescence immunoassay (PCFIA). Thromb Haemost. 1997;77(1):109‐118.
Berrettini M, Lammle B, White T, et al. Detection of in vitro and in vivo cleavage of high molecular weight kininogen in human plasma by immunoblotting with monoclonal antibodies. Blood. 1986;68(2):455‐462.
Suffritti C, Zanichelli A, Maggioni L, Bonanni E, Cugno M, Cicardi M. High‐molecular‐weight kininogen cleavage correlates with disease states in the bradykinin‐mediated angioedema due to hereditary C1‐inhibitor deficiency. Clin Exp Allergy. 2014;44(12):1503‐1514.
Cugno M, Cicardi M, Agostoni A. Activation of the contact system and fibrinolysis in autoimmune acquired angioedema: a rationale for prophylactic use of tranexamic acid. J Allergy Clin Immunol. 1994;93(5):870‐876.
Matias I, Carta G, Murru E, Petrosino S, Banni S, Di Marzo V. Effect of polyunsaturated fatty acids on endocannabinoid and N‐acyl‐ethanolamine levels in mouse adipocytes. Biochim Biophys Acta. 2008;1781(1–2):52‐60.
Piscitelli F, Carta G, Bisogno T, et al. Effect of dietary krill oil supplementation on the endocannabinoidome of metabolically relevant tissues from high‐fat‐fed mice. Nutr Metab. 2011;8(1):51.
Kaplan AP, Joseph K. Pathogenic mechanisms of bradykinin mediated diseases: dysregulation of an innate inflammatory pathway. Adv Immunol. 2014;121:41‐89.
de Maat S, Bjorkqvist J, Suffritti C, et al. Plasmin is a natural trigger for bradykinin production in patients with hereditary angioedema with factor XII mutations. J Allergy Clin Immunol. 2016;138(5):1414.
Ivanov I, Matafonov A, Sun MF, et al. A mechanism for hereditary angioedema with normal C1 inhibitor: an inhibitory regulatory role for the factor XII heavy chain. Blood. 2019;133(10):1152‐1163.
Muzorewa TT, Buerk DG, Jaron D, Barbee KA. Coordinated regulation of endothelial calcium signaling and shear stress‐induced nitric oxide production by PKCbeta and PKCeta. Cell Signal. 2021;87:110125.
Wang Y, Zhou H, Wu B, Zhou Q, Cui D, Wang L. Protein kinase C isoforms distinctly regulate propofol‐induced endothelium‐dependent and endothelium‐independent vasodilation. J Cardiovasc Pharmacol. 2015;66(3):276‐284.
Demirturk M, Gelincik A, Cinar S, et al. Increased eNOS levels in hereditary angioedema. Int Immunopharmacol. 2014;20(1):264‐268.
Baggelaar MP, Maccarrone M, van der Stelt M. 2‐Arachidonoylglycerol: a signaling lipid with manifold actions in the brain. Prog Lipid Res. 2018;71:1‐17.
Simard M, Archambault AS, Lavoie JC, Dumais E, Di Marzo V, Flamand N. Biosynthesis and metabolism of endocannabinoids and their congeners from the monoacylglycerol and N‐acyl‐ethanolamine families. Biochem Pharmacol. 2022;205:115261.
Pacher P, Batkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev. 2006;58(3):389‐462.
Di Marzo V, Melck D, De Petrocellis L, Bisogno T. Cannabimimetic fatty acid derivatives in cancer and inflammation. Prostaglandins Other Lipid Mediat. 2000;61(1–2):43‐61.
Di Marzo V, Maccarrone M. FAAH and anandamide: is 2‐AG really the odd one out? Trends Pharmacol Sci. 2008;29(5):229‐233.
Staiano RI, Loffredo S, Borriello F, et al. Human lung‐resident macrophages express CB1 and CB2 receptors whose activation inhibits the release of angiogenic and lymphangiogenic factors. J Leukoc Biol. 2016;99(4):531‐540.
Kawakami T, Xiao W. Phospholipase C‐beta in immune cells. Adv Biol Regul. 2013;53(3):249‐257.